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Interventional Cardiology
Frequent Post-PCI Events in Poor Responders to Clopidogrel
Multiple studies have shown that the magnitude of the response to clopidogrel isvariable, but the clinical significance of this finding remains uncertain. Bliden
and colleaguesmeasured pre-percutaneous coronary intervention (PCI) platelet aggre-
gation in patients on chronic clopidogrel who were followed for 1 year. Their criteria
identified 22% of patients as nonresponders who were 30 times more likely to suffer a
subsequent event, with higher risk in both the first 30 days and the subsequent 11
months. This study suggests that measuring the effectiveness of clopidogrel-induced
platelet inhibition identifies patients at increased risk for post-PCI ischemic complica-
tions. See page 657. See figure.
Heart Failure
Ultrafiltration Reduces Rehospitalization for CHF
Ultrafiltration is an emerging alternative to loop diuretics for patients with fluidoverload. Costanzo and colleagues performed a randomized, multicenter trial
comparing ultrafiltration with standard diuretic therapy in 200 heart failure patients
admitted with volume overload. At 48 h, weight loss and net fluid loss were both
significantly greater in the ultrafiltration group, though symptoms of CHF improved
similarly in both groups. Adverse event rates were similar. Subjects treated with
ultrafiltrationwere44%less likely tobe rehospitalizedover thenext 90days.Thesedata
indicate that in decompensatedheart failure, ultrafiltration safely produces greater fluid
loss than intravenous diuretics over the first 48 h, andmay have sustained benefits over
the next 90 days. See page 675.
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Heart Failure
Severity of Diastolic Dysfunction Predicts Outcomes
There is limited evidence regarding the significance of echo evidence of diastolicdysfunction (DD) in predicting outcomes in patients with HF and preserved
systolic function (HF-PSF). Persson and colleagues examined echo and BNP results in
over 300 patients enrolled in the CHARMPreserved Study.DDwas found in 67%of
study subjects, pseudonormal or restrictive filling in 44%. Over the next 18 months,
deathor readmission for heart failure correlated stronglywith the severity ofDD.These
results demonstrate the prognostic significance of echo DD in HF-PSF patients, and
suggest that an elevated BNPmay be a reliablemethod for distinguishing normal from
pseudo-normal filling patterns. See page 687. See figure.
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Preclinical Study
Everolimus-Eluting Stents May Stabilize Plaques
Macrophages in atherosclerotic plaques are known to secrete proteolytic enzymesthat can lead to rupture of the fibrous cap. Verheye and colleagues studied the
effects of everolimus on the composition of atherosclerotic plaques. The first experi-
ment involvedplacing both control stents and everolimus coated stents in rabbit aortas,
which demonstrated that everolimus reduced the number of macrophages over the
next 4weeks. Further studies confirmed that everolimus, by inhibiting themammalian
target of rapamycin (mTOR) protein, resulted in programmed cell death in macro-
phages but not smooth muscle cells. Stent-based delivery of an mTOR inhibitor
appears to be a promising method to selectively removemacrophages from atheroscle-
rotic plaques and thereby improve plaque stability. See page 706. See figure.
